Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Jul 1;26(19):3138-46.
doi: 10.1200/JCO.2007.12.7597. Epub 2008 May 12.

Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number

Francis P Worden  1 , Bhavna Kumar, Julia S Lee, Gregory T Wolf, Kitrina G Cordell, Jeremy M G Taylor, Susan G Urba, Avraham Eisbruch, Theodoros N Teknos, Douglas B Chepeha, Mark E Prince, Christina I Tsien, Nisha J D'Silva, Kun Yang, David M Kurnit, Heidi L Mason, Tamara H Miller, Nancy E Wallace, Carol R Bradford, Thomas E Carey
Affiliations

Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number

Francis P Worden et al. J Clin Oncol. .

Abstract

Purpose: To test induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CRT) or surgery/radiotherapy (RT) for advanced oropharyngeal cancer and to assess the effect of human papilloma virus (HPV) on response and outcome.

Patients and methods: Sixty-six patients (51 male; 15 female) with stage III to IV squamous cell carcinoma of the oropharynx (SCCOP) were treated with one cycle of cisplatin (100 mg/m(2)) or carboplatin (AUC 6) and with fluorouracil (1,000 mg/m(2)/d for 5 days) to select candidates for CRT. Those achieving a greater than 50% response at the primary tumor received CRT (70 Gy; 35 fractions with concurrent cisplatin 100 mg/m(2) or carboplatin (AUC 6) every 21 days for three cycles). Adjuvant paclitaxel was given to patients who were complete histologic responders. Patients with a response of 50% or less underwent definitive surgery and postoperative radiation. Pretreatment biopsies from 42 patients were tested for high-risk HPV.

Results: Fifty-four of 66 patients (81%) had a greater than 50% response after IC. Of these, 53 (98%) received CRT, and 49 (92%) obtained complete histologic response with a 73.4% (47 of 64) rate of organ preservation. The 4-year overall survival (OS) was 70.4%, and the disease-specific survival (DSS) was 75.8% (median follow-up, 64.1 months). HPV16, found in 27 of 42 (64.3%) biopsies, was associated with younger age (median, 55 v 63 years; P = .016), sex (22 of 30 males [73.3%] and five of 12 females [41.7%]; P = .08), and nonsmoking status (P = .037). HPV titer was significantly associated with IC response (P = .001), CRT response (P = .005), OS (P = .007), and DSS (P = .008).

Conclusion: Although the numbers in this study are small, IC followed by CRT is an effective treatment for SCCOP, especially in patients with HPV-positive tumors; however, for patients who do not respond to treatment, alternative treatments must be developed.

PubMed Disclaimer

Figures

Fig 1
Fig 1
UMCC 9921 study schema. CDDP, cisplatin; FU, fluorouracil; CR, complete response; PR, partial response; XRT, radiation therapy. (*) If the original neck node was > 3 cm, selective neck dissection was performed. (**) If a positive biopsy was obtained, primary site resection with or without neck dissection was performed.
Fig 2
Fig 2
Schema showing the response of patients according to treatment. Endoscopy*, endoscopy with biopsy. DoD, died of disease; Sec, second; DM, distant metastases; CRT, concurrent chemotherapy/radiation therapy; XRT, radiation therapy; LR, local/regional unresectable; CR/PR, complete response/partial response (> 50% response to induction chemotherapy); < PR, stable disease or progressive disease (≤ 50% response to induction chemotherapy); DPD, dihydropyrimidine dehydrogenase deficiency; DoC, died of other causes.
Fig 3
Fig 3
(A) Overall survival and (B) disease-specific survival plots of patients (n = 66). (C) Disease-specific survival based on sex. (D) Disease-specific survival based on smoking status. (E) Response to induction chemotherapy based on mean human papilloma virus (HPV) titers; blue box, interquartile range (25th to 75th percentile), not including outliers; horizontal black line, median; range bars, range of minimum to maximum observations, not including outliers; red dot, mean; blue dot, outlier. (F) Disease-specific survival according to HPV16 titers. CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Shiboski CH, Schmidt BL, Jordan RC. Tongue and tonsil carcinoma: Increasing trends in the US population ages 20-44 years. Cancer. 2005;103:1843–1849. - PubMed
    1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43–66. - PubMed
    1. Bagnardi V, Blangiardo M, La Vecchia C, et al. Alcohol consumption and the risk of cancer: A meta-analysis. Alcohol Res Health. 2001;25:263–270. - PMC - PubMed
    1. Lewin F, Norell SE, Johansson H, et al. Smoking tobacco, oral snuff, and alcohol in the etiology of squamous cell carcinoma of the head and neck: A population-based case-referent study in Sweden. Cancer. 1998;82:1367–1375. - PubMed
    1. D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med. 2007;356:1944–1956. - PubMed

Publication types

MeSH terms